Literature DB >> 11106325

K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification.

S J Clayton1, F M Scott, J Walker, K Callaghan, K Haque, T Liloglou, G Xinarianos, S Shawcross, P Ceuppens, J K Field, J C Fox.   

Abstract

BACKGROUND: The use of sensitive molecular techniques to detect rare cells in a population is of increasing interest to the molecular pathologist, but detection limits often are poorly defined in any given molecular assay. We combined the approaches of real-time quantitative PCR with ARMS(TM) allele-specific amplification in a novel assay for detecting mutant K-ras sequences in clinical samples.
METHODS: ARMS reactions were used to detect seven commonly occurring mutations in the K-ras oncogene. These mutations produce amino acid changes in codon 12 (Gly to Ala, Arg, Asp, Cys, Ser, or Val) and codon 13 (Gly to Asp). A control reaction was used to measure the total amount of amplifiable K-ras sequence in a sample so that the ratio of mutant to wild-type sequence could be measured. Quantitative data were confirmed for a selection of samples by an independent cloning and sequencing method. The assay was used to analyze 82 lung tumor DNA samples.
RESULTS: The assay detected K-ras mutations in 44% of adenocarcinomas, which is equivalent to frequencies reported in the literature using ultrasensitive techniques. Forty-six percent of squamous carcinomas were also positive. The ratio of mutant sequence in the tumor DNA samples was 0.04-100%.
CONCLUSIONS: The assay is homogeneous, with addition of tumor DNA sample being the only step before results are generated. The quantitative nature of the assay can potentially be used to define the analytical sensitivity necessary for any specified diagnostic application of K-ras (or other) point mutation detection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106325

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  24 in total

1.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Authors:  Wilko Weichert; Christiane Schewe; Annika Lehmann; Christine Sers; Carsten Denkert; Jan Budczies; Albrecht Stenzinger; Hans Joos; Olfert Landt; Volker Heiser; Christoph Röcken; Manfred Dietel
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

2.  KRAS assay selection: sensitivity and accuracy in clinical application.

Authors:  Marta Herreros-Villanueva; Gaurav Aggarwal
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

3.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Liying Yan; Mami Cantor; Chungdak Namgyal; Mari Mino-Kenudson; Gregory Y Lauwers; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

4.  A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.

Authors:  Bárbara Angulo; Elena García-García; Rebeca Martínez; Ana Suárez-Gauthier; Esther Conde; Manuel Hidalgo; Fernando López-Ríos
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

5.  Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.

Authors:  Alois H Lang; Heinz Drexel; Simone Geller-Rhomberg; Nicole Stark; Thomas Winder; Kathrin Geiger; Axel Muendlein
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

6.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.

Authors:  Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

Review 7.  Basic principles of fluorescence and energy transfer applied to real-time PCR.

Authors:  Larry E Morrison
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

8.  A comparability study of 5 commercial KRAS tests.

Authors:  Kelly Oliner; Todd Juan; Sid Suggs; Michael Wolf; Ildiko Sarosi; Daniel J Freeman; Tibor Gyuris; Will Baron; Andreas Bakker; Alex Parker; Scott D Patterson
Journal:  Diagn Pathol       Date:  2010-04-16       Impact factor: 2.644

Review 9.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

10.  Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

Authors:  Sophie Archambeault; Nikki J Flores; Ayami Yoshimi; Christian P Kratz; Miriam Reising; Alexandra Fischer; Peter Noellke; Franco Locatelli; Petr Sedlacek; Christian Flotho; Marco Zecca; Peter D Emanuel; Robert P Castleberry; Charlotte M Niemeyer; Peter Bader; Mignon L Loh
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.